A large study ties Ozempic and Mounjaro to a side effect users never saw coming

Weight-loss and diabetes drugs such as Ozempic and Mounjaro have been studied for their effects on blood sugar, appetite, and even the heart. A large new analysis points to a less expected consequence: hair loss. Researchers who combed through the health records of tens of thousands of patients found that people taking this class of drugs developed alopecia more often than those on two other common diabetes treatments. The increase was statistically clear, though the researchers stressed that the overall chance of losing hair remained low.

The finding lands amid soaring use of these medicines, which has pushed millions of new patients onto them in recent years. Because so many people now take the drugs, even a modest shift in the odds of a side effect can translate into a meaningful number of affected users, which is part of why the researchers set out to measure the risk directly rather than rely on scattered anecdotes.

A target trial emulation built from Penn Medicine records

The study, published in The BMJ, used a method called target trial emulation, which applies the design logic of a randomized trial to real-world medical records in an effort to make fairer comparisons. The team analyzed electronic health records from the University of Pennsylvania health system covering adults with type 2 diabetes who started treatment between January 2019 and September 2024. Rather than compare drug users against people taking nothing, the researchers matched them against patients starting other diabetes medicines, a design that helps isolate the drug’s effect from the underlying condition.

The drugs in question are GLP-1 receptor agonists, a group that includes semaglutide, sold as Ozempic and Wegovy, and tirzepatide, sold as Mounjaro and Zepbound. The analysis set them against two rival classes: SGLT-2 inhibitors and DPP-4 inhibitors. One comparison included 12,004 people on GLP-1 drugs and 15,221 on SGLT-2 inhibitors, while a separate comparison pitted 11,964 GLP-1 users against 11,233 people taking DPP-4 inhibitors. Before adjustment, the groups differed in ways that could skew the results, so the researchers accounted for age, sex, ethnicity, body mass index, other medications, and pre-existing conditions.

How much the risk rose

After those adjustments, the pattern held. As summarized in a research report from ScienceDaily drawing on the BMJ study, GLP-1 use was associated with a 37 percent higher risk of alopecia than SGLT-2 inhibitor use, at 6.91 versus 5.04 cases per 1,000 person-years. Compared with DPP-4 inhibitors, the risk was 68 percent higher, at 6.53 versus 3.89 cases per 1,000 person-years. Those are relative increases layered on a low baseline, which is why the authors were careful to frame the absolute risk as small even as the relative difference reached statistical significance.

A closer look narrowed the effect to one category of hair loss. The elevated risk was confined to non-scarring alopecia, the form in which the hair follicles remain intact and regrowth is possible. Within that category, the risk was 53 percent higher among GLP-1 users than among SGLT-2 inhibitor users and 72 percent higher than among DPP-4 inhibitor users. The distinction matters to patients, because non-scarring hair loss often reverses once its trigger is removed, unlike scarring forms that permanently destroy the follicle.

Why rapid weight loss may disrupt the hair cycle

The study was designed to detect an association, not to explain it, and the authors did not establish a mechanism. They did, however, point to several plausible explanations rooted in how the body responds to fast weight change. Rapid weight loss is a well-established cause of increased hair shedding, a condition in which stress pushes a large share of follicles into their resting phase at once, leading to noticeable thinning weeks or months later.

Nutrition may play a role as well. Sharp reductions in food intake can leave the body short on iron or zinc, both of which are needed for normal hair growth, and deficiencies in either can interfere with the follicle’s cycle. Hormonal shifts that accompany weight loss or the drugs themselves could also contribute. Because the GLP-1 drugs tend to produce faster and larger weight reductions than many alternatives, that same potency may be what places extra stress on hair follicles, though the researchers cautioned that more work is needed to confirm any of these pathways.

The limits of an observational study

The authors were candid about what their data could not show. Because the analysis relied on medical records rather than a controlled experiment, it cannot prove that the drugs directly caused the hair loss; unmeasured factors could still be influencing the results. The records also lacked the detail needed to gauge how severe or extensive the alopecia was, or how long it lasted, and the team could not track whether hair grew back after patients stopped the medication.

Even with those caveats, the researchers described their work as rigorous, noting that it drew on high-quality data from a large and representative patient population and that the findings stayed consistent across additional analyses. Their conclusion was measured: the results extend earlier anecdotal safety signals and offer more systematic evidence to inform clinical awareness of the side effect. Regulators have already moved in a similar direction, with hair loss increasingly flagged among the potential adverse reactions listed for drugs in this class. For patients weighing the substantial metabolic benefits of GLP-1 therapy, the message is not to abandon treatment but to go in informed, and to raise any shedding with a clinician who can check for reversible causes such as low iron.

This article was produced with AI assistance and reviewed by Morning Overview editors.

More from Morning Overview